Company Overview and News

2
Cummins India Limited - Investor Presentation

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

2
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

38
Cummins (CMI) Down 5.7% Since Earnings Report: Can It Rebound?

2018-05-31 zacks
A month has gone by since the last earnings report for Cummins Inc. (CMI - Free Report) . Shares have lost about 5.7% in that time frame.
CMQMY CMI EXR

2
Competition dims Cummins India’s Q4 performance

2018-05-31 livemint
Notwithstanding a dull March quarter (Q4), missing estimates on all counts, multinational capital goods manufacturer Cummins India Ltd’s management struck an optimistic outlook for the coming year. They guided for an 8-10% growth in fiscal year 2019 (FY19) on expectations of strong sales in engines for the power generator and industrial segments. But the Street is not convinced and the company’s shares have fallen by 4% since its results were announced.
500480 CMQMY CUMMINSIND

2
Cummins India Limited - Clarification - Financial Results

2018-05-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

2
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-23 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

35
UPDATE 1-U.S. extends deadline for sanctions on Russian van maker GAZ

2018-05-22 reuters
WASHINGTON/MOSCOW (Reuters) - The United States on Tuesday gave American customers of Russia’s biggest van manufacturer GAZ (GAZA.MM) more time to comply with sanctions, further backing away from its initially uncompromising stance on GAZ’s owner, Russian tycoon Oleg Deripaska.
CMQMY CMI

2
Cummins India Limited - Change in Director(s)

2018-05-21 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

2
Cummins India Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-05-17 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

38
Diversified Manufacturer Wabash National Corporation Appoints New General Counsel

2018-05-16 globenewswire
LAFAYETTE, Ind. , May 16, 2018 (GLOBE NEWSWIRE) -- Wabash National Corporation (NYSE:WNC), a diversified industrial manufacturer and a leading producer of semi-trailers and liquid transportation systems, today announced the appointment of Melanie D. Margolin as Senior Vice President and General Counsel. She will oversee all of the company’s legal affairs worldwide in areas such as corporate, commercial, regulatory, intellectual property, ethics, compliance and litigation.
CMQMY WNC CMI

40
Cummins (CMI) to Form JV With JAC Motors & Offer Engines

2018-05-15 zacks
Cummins Inc. (CMI - Free Report) announced that it will form a 50:50 joint venture (JV) with Anhui Jianghuai Automobile Co. Ltd. (JAC Motors). Additionally, Cummins acquired 50% equity of JAC-Navistar Diesel Engine Company from Navistar International Corporation (NAV - Free Report) . JAC Motors is an auto manufacturer with full-line independent brands in China. Per management, both the companies believe in similar values and focus on offering right power solutions to their customers.
NAV CMQMY NAV.PRD FCAU CMI

35
Fiat Chrysler CEO reprimands colleague for commenting on emissions

2018-05-15 channelnewsasia
WASHINGTON: Fiat Chrysler Chief Executive Officer Sergio Marchionne reprimanded the company's top U.S. spokesman for issuing press releases about Fiat's vehicle emissions practices days after Volkswagen's disclosure in September 2015 that the German automaker had used illegal software to evade emissions tests, documents released Monday show.
CMQMY CMI

35
Fiat Chrysler CEO reprimands colleague for commenting on emissions

2018-05-15 reuters
WASHINGTON (Reuters) - Fiat Chrysler Chief Executive Officer Sergio Marchionne reprimanded the company’s top U.S. spokesman for issuing press releases about Fiat’s vehicle emissions practices days after Volkswagen’s (VOWG_p.DE) disclosure in September 2015 that the German automaker had used illegal software to evade emissions tests, documents released Monday show.
CMQMY CMI

35
Hexagon Composites' (HXGCF) CEO Jon Engeset on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Welcome everybody here in the studio and those joining the webcast. It’s my pleasure to take you through Hexagon Composites’ Quarter One 2018 Earnings Broadcast. I will start with the, as usual, group highlights, the financials and segment overview. And we’ll also have an update on the hydrogen-related investments. These are key strategic area for Hexagon at the moment. And also, Jon Erik, will join us for the outlook, and we’ll both take any Q&A.
CMQMY CMI

2
Cummins India Limited - Updates

2018-05-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
500480 CMQMY CUMMINSIND

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

4h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...